Company Profile For Sanofi-Aventis S.A.

Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. The Company's business includes two main activities: pharmaceuticals and human vaccines through sanofi pasteur. In its pharmaceutical activity, Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. On September 1, 2008, Sanofi-Aventis acquired the Australian company, Symbion CP Holdings Pty Ltd (Symbion Consumer). On September 25, 2008, it acquired Acambis plc. In January 2009, the Company sold its French plant of Colomiers to French pharmaceutical company Unither.In April 2009, the Company acquired Mexican generic company, Laboratorios Kendrick.

BRIEF: For the nine months ended 30 September 2009, Sanofi-Aventis SA's total revenue increased 8% to EUR23.02B. Net income for the period increased 11% to EUR4.06B. Total revenue reflects increased demand for the Company's products and services. Net income for the period benefited from an increase in research and development as well as an increase in selling and general and restructuring costs.

Sanofi-Aventis S.A.
174 avenue de France
cedex 13
Paris     75635
P: +331.53774000
F: +331.53774296

98213